{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:20:42Z","timestamp":1761157242834},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"Supplement_E","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dyslipidaemias and in particular elevated plasma low-density lipoprotein cholesterol (LDL-C) levels are major risk factors for atherosclerotic cardiovascular disease (ASCVD). Indeed, the more LDL-C is reduced the larger will be the ASCVD risk reduction. Although statins represent the first-line intervention to reduce the atherosclerotic burden driven by raised levels of LDL-C, adherence is not optimal and most patients do not follow guidelines and recommended doses. Thus, to achieve optimal LDL-C goals, especially in very high-risk patients, there is a need for new and safe agents, more tolerable than statins with low risk of myalgia. Thus, the present review will address the most recent clinical trials with bempedoic acid and inclisiran. Bempedoic acid is an oral drug acting at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and not associated with muscular side effects. Inclisiran, the first-in-class small interfering RNA-based approach, has the ability to effectively reduce LDL-C by inhibiting the hepatic synthesis of proprotein convertase subtilisin\/kexin type 9, with the advantage of requiring subcutaneous of a single dose on Day 1, Day 90, and every 6\u2009months thereafter.<\/jats:p>","DOI":"10.1093\/eurheartj\/suab090","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:44:17Z","timestamp":1633945457000},"page":"E59-E62","source":"Crossref","is-referenced-by-count":7,"title":["New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran"],"prefix":"10.1093","volume":"23","author":[{"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare Riccardo","family":"Sirtori","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"Centro Dislipidemie, ASST Grande Ospedale Metropolitano Niguarda Ca\u2019 Granda, Milano, Italy"},{"name":"Department of Pharmaceutical and Pharmacological Sciences, Universit\u00e0 degli Studi di Padova, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[{"name":"IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"2021101106042148500_suab090-B1","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2021101106042148500_suab090-B2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2021101106042148500_suab090-B3","article-title":"EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","author":"Ray","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2021101106042148500_suab090-B4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021101106042148500_suab090-B5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"2021101106042148500_suab090-B6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2021101106042148500_suab090-B7","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"2021101106042148500_suab090-B8","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2021101106042148500_suab090-B9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"key":"2021101106042148500_suab090-B10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"2021101106042148500_suab090-B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2021101106042148500_suab090-B12"},{"key":"2021101106042148500_suab090-B13","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: the era of RNA-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol Res"},{"key":"2021101106042148500_suab090-B14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"2021101106042148500_suab090-B15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2021101106042148500_suab090-B16","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.118.034710","article-title":"Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: prespecified secondary end points in ORION 1","volume":"138","author":"Ray","year":"2018","journal-title":"Circulation"},{"key":"2021101106042148500_suab090-B17","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2021101106042148500_suab090-B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2020.09.021","article-title":"Estimation of the major cardiovascular events prevention with Inclisiran","volume":"313","author":"Cordero","year":"2020","journal-title":"Atherosclerosis"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/23\/Supplement_E\/E59\/40544547\/suab090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/23\/Supplement_E\/E59\/40544547\/suab090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:44:38Z","timestamp":1633945478000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/23\/Supplement_E\/E59\/6386310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":18,"journal-issue":{"issue":"Supplement_E","published-online":{"date-parts":[[2021,10,8]]},"published-print":{"date-parts":[[2021,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suab090","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,10,1]]}}}